Can we predict the risk of venous thromboembolism in patients with Cushing's syndrome: a nationwide cohort analysis.

Purpose: Patients with Cushing's syndrome (CS) have an increased venous thromboembolism (VTE) risk with most studies focusing on the perioperative period. The purpose of this study was to assess the 5-year VTE risk and identify predictors of VTE at CS diagnosis.

Methods: A comparative nationwide retrospective cohort study of 609 patients (mean age 48.

Europium and Terbium Benzene-1,2,4,5-Tetracarboxylates: Synthesis Peculiarities, Crystal Structures, and Luminescent Thermometry up to 400 °C.

In this study, we successfully obtained for the first time a luminescent organic-based thermometer that exhibits high reproducibility, stability, and functionality up to 400 °C. Our approach involved the selection of novel highly emissive and thermally stable MOFs KEu(btec)(HO) and dehydrated KTb(btec), btec = benzene-1,2,4,5-tetracarboxylate, along with the highly thermally stable copolyimide P84 = 80% methylphenylene-diamine + 20% methylene as the matrix; luminescence lifetime was selected as a temperature-dependent parameter due to its versatility in diverse environmental conditions. Synthesis peculiarities were studied for various lanthanide benzene-1,2,4,5-tetracarboxylates, and the crystal structures of KEu(btec)(HO) and KTb(btec) were determined by Rietveld refinement from powder X-ray diffraction data.

Higher risk and earlier onset glaucoma in Cushing's syndrome.

Purpose: Glaucoma incidence in patients with endogenous Cushing's syndrome (CS) has never been established. We aim to assess the risk for glaucoma among CS patients compared to controls and determine the age of disease onset.

Methods: A nationwide retrospective matched-cohort study of patients with endogenous CS diagnosed between 2000 and 2023.

Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia.

Purpose: Given prolactin's (PRL) multifaceted roles in mammary tissue, an association between hyperprolactinemia and breast cancer has been hypothesized. Despite previous studies not identifying this risk, we aimed to investigate whether a connection exists.

Methods: This retrospective cohort study compared breast cancer incidence in patients with dopamine agonist (DA)-treated hyperprolactinemia versus matched controls in a 1:5 ratio.